PATENT CLAIM ANALYSIS

Application Number: 16234364
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-06
Patent Classification: ["514", "211000"]

Abstract:
The present invention relates to crystal modifications of N-{(2R)-2-[({[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl]oxy}acetyl)amino]-2-phenylethanolyl}glycine (elobixibat).

Claim (Index 18):
The crystalline form according to  claim 16 , wherein the crystalline form has an XRPD pattern, obtained with CuK\u03b1 1 -radiation, with peaks at \u00b02\u03b8 positions 6.4\u00b10.2, 12.7\u00b10.2, 4.2\u00b10.2, 8.5\u00b10.2, 10.5\u00b10.2, 19.3\u00b10.2, and 19.5\u00b10.2, and with peaks at one or more \u00b02\u03b8 positions of: 4.8\u00b10.2, 5.9\u00b10.2, 12.1\u00b10.2, 12.4\u00b10.2, 13.3\u00b10.2, 13.6\u00b10.2, 17.7\u00b10.2, 19.9\u00b10.2, and 21.4\u00b10.2.

Metadata:
- Claim Count in Document: 41.0
- Percentile: 98.0
- Lexical Diversity: 1.37037
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15519808', '15134583', '15134586', '14429388', '15925270']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7496276127204444
- 35 USC 102 Novelty (BERT): 0.6025660811123507
- Combined Prediction Score: 0.7349214595596352
- Mean Citation Score: 364.651854
- Max Citation Score: 534.8228
- Similarity Product: 443.9344104621172

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test